Hyperliquid Strategies (PURR) Q3 2026 earnings summary

Executive summary

• Achieved strong Q3 results with a $152.5M net profit, driven by significant appreciation in HYPE token price and disciplined treasury strategy, scaling HYPE holdings to nearly 20M tokens.

• Completed exit from legacy Sonnet/bio-tech assets, retaining a 40% stake in Guidant BioTherapeutics.

• Launched validator partnership with Unit/Trade XYZ (Unit Labs), expanding ecosystem participation and recurring revenue streams.

• Focused on bringing real world assets and outcome markets on-chain, with HIP-3 and HIP-4 gaining traction.

• Maintains capital-efficient HYPE exposure and staking revenue growth as core priorities.

Financial highlights

• HYPE token price rose from $25.48 to $36.60 during Q3, resulting in an unrealized gain of $198.4M; 18.8M tokens held at quarter-end, increasing to 19.97M at $40.03 by April 29, 2026.

• Net income for the quarter was $152.5M, reversing a prior quarter loss of $304.5M; nine-month net loss after taxes was $165.4M due to prior period losses and write-offs.

• Cash and equivalents at quarter-end were $113.1M, down from $281.9M sequentially; HYPE digital assets increased from $327.6M to $689.0M.

• Generated $2.6M in staking revenue and $1M in interest income for the quarter; nine-month staking revenue totaled $3.1M.

• Stockholders’ equity at $743.5M as of March 31, 2026, with no debt.

Outlook and guidance

• Anticipates further growth from outcome markets (HIP-4), pre-IPO markets, portfolio margin, and validator revenue streams.

• Expects continued expansion of institutional partnerships, ecosystem engagement, and innovation in the Hyperliquid ecosystem.

• Ongoing evaluation of cash deployment between operating needs and further HYPE purchases, with a minimum cash reserve target of $25M.